Resolution
|
Total votes
for*
|
%
|
Total votes
against
|
%
|
Total votes
cast
|
Votes
withheld**
|
|
1
|
To
receive and adopt the 2016 Annual Report
|
3,554,183,464
|
97.22
|
101,455,389
|
2.78
|
3,655,638,853
|
4,387,214
|
2
|
Approve
the Annual report on remuneration
|
3,463,239,643
|
96.39
|
129,558,994
|
3.61
|
3,592,798,637
|
67,227,431
|
3
|
Approve
the Remuneration policy
|
3,422,452,218
|
95.23
|
171,330,252
|
4.77
|
3,593,782,470
|
66,243,598
|
4
|
Election
of Emma Walmsley
|
3,634,697,039
|
99.38
|
22,652,327
|
0.62
|
3,657,349,366
|
2,676,702
|
5
|
Election
of Dr Vivienne Cox
|
3,585,205,455
|
98.03
|
72,167,674
|
1.97
|
3,657,373,129
|
2,653,239
|
6
|
To
elect Dr Patrick Vallance
|
3,629,796,597
|
99.25
|
27,494,401
|
0.75
|
3,657,290,998
|
2,735,337
|
7
|
Re-election
of Sir Philip Hampton
|
3,628,585,104
|
99.22
|
28,393,827
|
0.78
|
3,656,978,931
|
3,047,437
|
8
|
Re-election
of Professor Sir Roy Anderson
|
3,625,292,635
|
99.12
|
32,058,752
|
0.88
|
3,657,351,387
|
2,674,980
|
9
|
Re-election
of Vindi Banga
|
3,581,285,228
|
97.92
|
76,000,048
|
2.08
|
3,657,285,276
|
2,741,092
|
10
|
Re-election
of Simon Dingemans
|
3,518,149,283
|
96.20
|
139,147,225
|
3.80
|
3,657,296,508
|
2,729,860
|
11
|
Re-election
of Lynn Elsenhans
|
3,638,701,603
|
99.49
|
18,607,222
|
0.51
|
3,657,308,825
|
2,710,187
|
12
|
Re-election
of Dr Jesse Goodman
|
3,639,142,174
|
99.50
|
18,139,405
|
0.50
|
3,657,281,579
|
2,714,188
|
13
|
Re-election
of Judy Lewent
|
3,510,396,677
|
95.98
|
146,948,919
|
4.02
|
3,657,345,596
|
2,680,772
|
14
|
Re-election
of Urs Rohner
|
3,575,150,146
|
97.76
|
82,080,983
|
2.24
|
3,657,231,129
|
2,795,239
|
15
|
Re-appointment
of auditors
|
3,589,897,930
|
98.70
|
47,405,837
|
1.30
|
3,637,303,767
|
22,722,600
|
16
|
Remuneration
of auditors
|
3,634,255,503
|
99.37
|
23,089,499
|
0.63
|
3,657,345,002
|
2,674,361
|
17
|
Authority
for the company to make donations to political organisations and
incur political expenditure
|
3,590,068,747
|
98.21
|
65,556,654
|
1.79
|
3,655,625,401
|
4,400,967
|
18
|
Authority
to allot shares
|
3,545,752,292
|
96.96
|
111,083,355
|
3.04
|
3,656,835,647
|
3,190,721
|
19
|
Disapplication
of pre-emption rights - general power***
|
3,579,962,643
|
97.94
|
75,432,563
|
2.06
|
3,655,395,206
|
4,624,157
|
20
|
Disapplication
of pre-emption rights - in connection with an acquisition or
specified capital investment***
|
3,395,638,484
|
92.96
|
257,114,976
|
7.04
|
3,652,753,460
|
7,265,904
|
21
|
Authority
for the company to purchase its own shares***
|
3,607,672,499
|
98.68
|
48,202,613
|
1.32
|
3,655,875,112
|
4,151,256
|
22
|
Exemption
from statement of senior statutory auditor's name
|
3,629,354,814
|
99.28
|
26,480,369
|
0.72
|
3,655,835,183
|
4,198,037
|
23
|
Authorise
reduced notice of a general meeting other than an AGM***
|
3,407,170,884
|
93.19
|
248,934,681
|
6.81
|
3,656,105,565
|
3,920,802
|
24
|
Approve
the GlaxoSmithKline 2017 Performance Share Plan
|
3,515,643,781
|
96.16
|
140,281,237
|
3.84
|
3,655,925,018
|
4,101,350
|
25
|
Approve
the 2017 GlaxoSmithKline Deferred Annual Bonus Plan
|
3,579,310,888
|
97.97
|
74,224,589
|
2.03
|
3,653,535,477
|
6,490,891
|
*
|
Includes
discretionary votes.
|
**
|
A vote
withheld is not a vote in law and is not counted in the calculation
of the proportion of votes "For" or "Against" a
resolution.
|
***
|
Indicates
Special Resolutions requiring a 75% majority.
|
|
GSK's
Seventeenth
AGM
(2017)
|
GSK's
Sixteen AGM
(2016)
|
Issued
share capital (excluding Treasury Shares)
|
4,917,502,476
|
4,871,555,095
|
Total
votes cast and votes withheld lodged as a % of GSK's issued share
capital (excluding Treasury Shares)
|
74.43%
|
76.15%
|
Total
shareholder population
|
116,502
|
132,85
|
Total
number of proxies lodged
|
7,336
|
8,020
|
% of
shareholders who lodged proxies
|
6.30%
|
6.03%
|
Number
of shareholders, corporate representatives and proxies who attended
the AGM
|
435
|
448
|
GSK enquiries:
|
|
|
|
UK
Media enquiries:
|
David
Mawdsley
|
+44 (0)
20 8047 5502
|
(London)
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington)
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Sarah
Webster
|
+44 (0)
20 8047 0246
|
(London)
|
|
Tom
Curry
|
+1 215
751 5419
|
(Philadelphia)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
04, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|